Biosimilars in rheumatology and other fields of medicine
نویسندگان
چکیده
منابع مشابه
[Biosimilars in rheumatology and other fields of medicine].
Biosimilars are follow-up versions of innovative medicines with proved high similarity to the reference product. There may be some minor differences in clinically inactive components of a molecule which can be clinically significant, but they do not substantially affect the high resemblance to the original drug in their safety and potency. Introduction of the biosimilars brings hope to reduce t...
متن کاملUse of Biologics and Biosimilars in Rheumatology.
Prior to the availability of biologics, synthetic DMARDs (Disease modifying anti-rheumatic drugs) were the mainstay of the treatment in rheumatology. With the introduction of biologics, the scenario is changing to become more promising. These drugs have innovative mechanism of action, based on the targeted inhibition of specific molecular or cellular targets directly involved in disease pathoge...
متن کاملBiosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Rheumatoid arthritis (RA) societal costs are high because the disease may cause not only restricted joint mobility, chronic pain, fatigue, and functional disability, but also psychological distress. Direct health care costs represent about one-fourth of all costs and are prevalently represented by in-patient care expenditures. The introduction of biologics disease-modifying anti-rheumatic drugs...
متن کاملThe changing landscape of biosimilars in rheumatology
Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at th...
متن کاملBiosimilars in rheumatology: the wind of change.
The wind of change is blowing in rheumatology. Rheumatologists may soon be exposed to ‘biosimilars’ of the medicines they routinely use as the European Medicines Agency (EMA) has recently issued its final guideline on biosimilar monoclonal antibodies (mAbs)—a product class of utmost importance for rheumatologists—and a biosimilar infliximab is currently under evaluation for marketing authorisat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Postępy Higieny i Medycyny Doświadczalnej
سال: 2014
ISSN: 1732-2693
DOI: 10.5604/17322693.1114028